姜正明,田留洋,刘新民,姚晶,苑飞,常三帅,闫云峰,张骞,胡彩娜,董建增,宋光远

• 1:首都医科大学附属北京安贞医院心脏瓣膜病介入中心国家心血管病临床医学研究中心
• 2:郑州大学第一附属医院心内科
• 3:首都医科大学附属北京安贞医院心力衰竭中心国家心血管病临床医学研究中心

摘要(Abstract)：

目的 总结股静脉途径经导管二尖瓣置换术治疗二尖瓣生物瓣毁损的初步经验。方法 回顾性总结2022年7月至2023年7月首都医科大学附属北京安贞医院心脏瓣膜病介入中心和郑州大学第一附属医院心内科77例因二尖瓣外科生物瓣毁损接受股静脉途径经导管二尖瓣生物瓣置换术的患者临床资料、影像学资料、手术操作及短期随访情况。结果 77例患者中男29例，女48例，平均年龄（71.3±5.6）岁，其中外科生物瓣重度狭窄合并重度反流7例，外科生物瓣重度狭窄4例，外科生物瓣重度反流66例；置入Sapien 3瓣膜23 mm 31例，26 mm 41例，29 mm 5例，器械成功率100%，平均手术时间（2.78±0.89）h，术后7 d平均跨瓣压差（3.95±1.92）mmHg，围手术期死亡0例，术后随访12个月共计2例患者出现中度（2+）反流。结论 股静脉途径行经导管二尖瓣置换术治疗外科高危二尖瓣生物瓣置换术后生物瓣毁损有良好的安全性和有效性。

关键词(KeyWords)： 经导管二尖瓣置换术;二尖瓣;生物瓣毁损;股静脉途径

Abstract:

Keywords:

基金项目(Foundation): 北京市医院管理中心“登峰”计划专项项目(DFL20240604)

作者(Author): 姜正明,田留洋,刘新民,姚晶,苑飞,常三帅,闫云峰,张骞,胡彩娜,董建增,宋光远

参考文献(References)：

• [1]Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J].Eur J Cardiothorac Surg, 2021, 60(4):727-800. DOI:10.1093/ejcts/ezab389.
• [2]Chung CH, Wang YJ, Lee CY. Epidemiology of heart valve disease in Taiwan[J]. Int Heart J, 2021, 62(5):1026-1034. DOI:10.1536/ihj.21-044.
• [3]Chompoosan C,Schr??der AS,H??llmer M,et al. Epidemiology of heart disease in English bull terriers and echocardiographic characteristics of mitral valve abnormalities[J]. J Small Anim Pract, 2022, 63(5):372-380. DOI:10.1111/jsap.13472.
• [4]Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse[J]. N Engl J Med, 1999,341(1):1-7. DOI:10.1056/NEJM199907013410101.
• [5]El Sabbagh A, Reddy YNV, Nishimura RA. Mitral valve regurgitation in the contemporary era:insights into diagnosis,management, and future directions[J]. JACC Cardiovasc Imaging, 2018, 11(4):628-643. DOI:10.1016/j.jcmg.2018.01.009.
• [6]Coffey S,Roberts-Thomson R,Brown A,et al. Global epidemiology of valvular heart disease[J]. Nat Rev Cardiol,2021,18(12):853-864. DOI:10.1038/s41569-021-00570-z.
• [7]Nielsen SL. Current status of transcatheter mitral valve repair therapies-from surgical concepts towards future directions[J].Scand Cardiovasc J, 2016, 50(5-6):367-376. DOI:10.1080/14017431.2016.1248482.
• [8]Harky A, Botezatu B, Kakar S, et al. Mitral valve diseases:pathophysiology and interventions[J]. Prog Cardiovasc Dis,2021, 67:98-104. DOI:10.1016/j.pcad.2021.03.008.
• [9]Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients[J]. N Engl J Med, 2019, 380(18):1695-1705. DOI:10.1056/NEJMoa1814052.
• [10]中国医师协会心血管内科医师分会结构性心脏病学组，亚太结构性心脏病俱乐部.中国经导管主动脉瓣置换术临床路径专家共识（2024版）[J].中国介入心脏病学杂志，2024, 32(11):601-617. DOI:10.3969/j.issn.1004-8812.2024.11.001.
• [11]Ribeiro HB,Webb JG,Makkar RR,et al. Predictive factors,management,and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation:insights from a large multicenter registry[J]. J Am Coll Cardiol, 2013, 62(17):1552-1562. DOI:10.1016/j.jacc.2013.07.040.
• [12]Tam DY, Sadri H. Annual budget impact analysis comparing self-expanding transcatheter and surgical aortic valve replacement in low-risk aortic stenosis patients[J]. Can J Cardiol, 2022, 38(10):1478-1484. DOI:10.1016/j.cjca.2022.06.005.
• [13]王越夫，姚彤，王伟鹏，等.再次二尖瓣置换术中严重心血管事件原因分析及应对措施[J].中国循环杂志，2008, 23(5):378-380.
• [14]Alperi A, Garcia S, Rodes-Cabau J. Transcatheter valvein-valve implantation in degenerated surgical aortic and mitral bioprosthesis:current state and future perspectives[J].Prog Cardiovasc Dis, 2022, 72:54-65. DOI:10.1016/j.pcad.2021.10.001.
• [15]尚小珂，虞奇峰，杨洁琰，等.经导管二尖瓣置换技术难点概述[J].中国介入心脏病学杂志，2023,31(8):609-614.DOI:10.3969/j.issn.1004-8812.2023.08.008.
• [16]王建安.国器智造拓疆土，结构性心脏病介入显锋芒[J].中国介入心脏病学杂志，2025,33(1):1-4. DOI:10.3969/j.issn.1004-8812.2025.01.001.
• [17]Babaliaros VC, Lederman RJ, Gleason PT, et al. The art of Sapien 3 transcatheter mitral valve replacement in valve-in-ring and valve-in-mitral-annular-calcification procedures[J]. JACC Cardiovasc Interv, 2021, 14(20):2195-2214. DOI:10.1016/j.jcin.2021.08.044.
• [18]Zahr F, Song HK, Chadderdon S, et al. 1-year outcomes following transfemoral transseptal transcatheter mitral valve replacement:Intrepid TMVR early feasibility study results[J]. JACC Cardiovasc Interv, 2023, 16(23):2868-2879.DOI:10.1016/j.jcin.2023.10.001.
• [19]Guerrero ME, Eleid MF, Wang DD, et al. 5-year prospective evaluation of mitral valve-in-valve, valve-in-ring, and valve-in-mac outcomes:Mitral trial final results[J]. JACC Cardiovasc Interv, 2023, 16(18):2211-2227. DOI:10.1016/j.jcin.2023.06.041.
• [20]Penteris M, Lampropoulos K. The Sapien M3 system for transcatheter mitral valve replacement:a new era begins[J].Cardiovasc Revasc Med, 2025,79:120-125. DOI:10.1016/j.carrev.2025.06.034.
• [21]Bozba??H，??elebi SA,Asfour M,et al. Percutaneous mitral valve-in-ring procedure in a case of severe mitral regurgitation repaired with a surgical flexible ring:a step-by-step description[J]. Turk Kardiyol Dern Ars, 2025, 53(1):68-72.DOI:10.5543/tkda.2024.41877.
• [22]Zubarevich A, Szczechowicz M, Arjomandi Rad A,et al. Conventional biological versus sutureless aortic valve prostheses in combined aortic and mitral valve replacement[J]. Life(Basel), 2023, 13(3):737. DOI:10.3390/life13030737.
• [23]Akodad M, Trpkov C, Cheung A, et al. Valve-in-valve transcatheter mitral valve replacement:a large first-in-human13-year experience[J]. Can J Cardiol, 2023, 39(12):1959-1970. DOI:10.1016/j.cjca.2023.08.018.
• [24]Fukui M, Okada A, Burns MR, et al. Deformation of transcatheter heart valves with mitral valve-in-valve[J].EuroIntervention, 2023, 19(11):e937-e947. DOI:10.4244/EIJ-D-23-00614.